Institutional sources predict that as corporate listing rules continue to be optimized, the number of applications for high-quality science and innovation enterprises on cutting-edge tracks such as semiconductors, biomedicine, and new energy will steadily increase, and the market investment paradigm will iterate along with it, gradually breaking away from the traditional idea of simply relying on short-term financial indicators, and putting more emphasis on the core technical barriers, scarce industrial value, and long-term growth potential of enterprises. The number of unprofitable science and innovation companies' declarations is expected to rise steadily in the future. The pace of distribution will remain stable and orderly, adhere to quality priorities, and there will be no “rush to the top” situation.

Institutional sources predict that as corporate listing rules continue to be optimized, the number of applications for high-quality science and innovation enterprises on cutting-edge tracks such as semiconductors, biomedicine, and new energy will steadily increase, and the market investment paradigm will iterate along with it, gradually breaking away from the traditional idea of simply relying on short-term financial indicators, and putting more emphasis on the core technical barriers, scarce industrial value, and long-term growth potential of enterprises. The number of unprofitable science and innovation companies' declarations is expected to rise steadily in the future. The pace of distribution will remain stable and orderly, adhere to quality priorities, and there will be no “rush to the top” situation.